[Cisplatin for malignant lymphoma--preliminary observation on 43 patients].
This paper reports the treatment results of cisplatin in 43 cases of malignant lymphoma. All were proved by pathology, cytology or X-ray and were non-resectable, disseminated advanced or refractory to routine anticancer drugs. The total dose of each course of cisplatin was usually 100-150 mg (2 mg/kg). One fifth or a tenth part of the dose was given with normal saline intravenously once a day. Complete remission rate was 9%, partial remission rate was 28%. Lymphosarcoma and reticulum cell sarcoma gave better results. During the treatment, anorexia, nausea and vomiting were common. Mild or moderate reduction of WBC and platelet was usually observed in the partial responsive cases but the depression on the bone marrow was relative mild. Cisplatin therapy did not cause marked renal dysfunction which was probably due to the hydration instituted. The anticancer action of cisplatin is similar to that of the alkylating agents but the participation of immunologic mechanism may also play a role.
D000328:Adult; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male
D002945:Cisplatin